NEW YORK, NY / ACCESSWIRE / November 24, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Credit Acceptance Corporation (NASDAQ:CACC)
Class Period: November 1, 2019 - August 28, 2020
Lead Plaintiff Deadline: December 1, 2020
According to the complaint, Credit Acceptance Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was topping off the pools of loans that they packaged and securitized with higher-risk loans; (ii) Credit Acceptance was making high-interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (iii) the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (iv) Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (v) as a result, the Company was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (vi) that, as a result of the foregoing, Defendants positive statements about the Company's business, operations, and adherence to appropriate laws and regulations were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in CACC: http://www.kleinstocklaw.com/pslra-1/credit-acceptance-corporation-loss-submission-form?id=11190&from=1
Raytheon Technologies Corporation (NYSE:RTX)
Class Period: February 10, 2016 - October 27, 2020
Lead Plaintiff Deadline: December 29, 2020
During the class period, Raytheon Technologies Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and inadequate internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon Company's Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and (6) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in RTX: http://www.kleinstocklaw.com/pslra-1/raytheon-technologies-corporation-loss-submission-form?id=11190&from=1
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Class Period: September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline: January 4, 2021
The ICPT lawsuit alleges that Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in ICPT: http://www.kleinstocklaw.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?id=11190&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm